MASLD and MASH
Metabolic dysfunction-associated steatotic liver disease and its new treatments.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 12, 14, 84, 124, 177.
New guidelines and consensus this year
- Splanchnic Vein Thrombosis after Metabolic and Bariatric Surgery: Chilean Position Statement of Hepatology and Bariatric Surgery societiesObes Surg2026 Sep 23
- AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction- and Alcohol-Associated Liver Disease: Expert ReviewClin Gastroenterol Hepatol2026 Sep 22
- Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statementGut2026 Sep 7
- Consensus statement on obesity management in liver transplantation candidatesUpdates Surg2026 Sep
- Prevention, surveillance, and early detection of hepatocellular carcinoma - a Brazilian multidisciplinary consensusArq Bras Cir Dig2026
All papers from the last 12 months
6,624 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Gut microbiota and metabolic characteristics in PWHIV with metabolic dysfunction-associated steatotic liver disease (MASLD)Virulence2027 DecPMID 42834659
- Recent Development of Endo-hepatologyDEN Open2027 AprPMID 42602295Review
- Targeted inhibition of inflammatory liver macrophages with a multifunctional nanoparticle ameliorates metabolic dysfunction-associated steatohepatitisBioact Mater2027 MarPMID 42835072
- Bioactive glasses-mediated ion therapy ameliorates hepatic osteodystrophy by reprogramming the liver-bone axisBioact Mater2027 FebPMID 42729454
- Babaodan ameliorates metabolic dysfunction-associated steatotic liver disease with co-modulation of FXR, NF-κB, and SLC22A7 in bile acid metabolismJ Ethnopharmacol2027 Jan 10PMID 42472598
- Optimal dose window, formulation efficacy, and molecular mechanisms of curcumin in MASLD animal models: A systematic review and three-level meta-analysisJ Ethnopharmacol2027 Jan 10PMID 42447971Meta-analysisSystematic review
- Gut microbiota shaping fatty liver disease progressionLife Sci Alliance2027 JanPMID 42864263Review
- Integrating Cardiovascular Risk Assessment into Metabolic Dysfunction-associated Steatotic Liver Disease Drug DevelopmentJ Clin Exp Hepatol2027 Jan-FebPMID 42857154
- Imeglimin provides dual hepatic and skeletal muscle protection in experimental MASH-associated sarcopeniaBiochim Biophys Acta Mol Basis Dis2027 JanPMID 42759777
- Sinusoidal endothelial cells orchestrate liver inflammation and lipid metabolism via USP12/CD36 axis being the target of celastrol therapyBiochim Biophys Acta Mol Basis Dis2027 JanPMID 42710599
More gastroenterology trends
All specialties →Fecal microbiota transplantation
Transferring stool microbiota to treat C. difficile and other conditions.
Key point: Fecal microbiota-based therapies should be offered after treatment of a second recurrence of Clostridioides difficile infection.
IL-23 inhibitors in IBD
Risankizumab, mirikizumab and guselkumab in Crohn's disease and ulcerative colitis.
EUS-guided interventions
Therapeutic procedures guided by endoscopic ultrasound.
Endoscopic bariatric therapy
Endoscopic sleeve gastroplasty and other endoscopic weight-loss procedures.
Early-onset colorectal cancer
Colorectal cancer in adults under 50.
Third-space endoscopy
Peroral endoscopic myotomy and endoscopic submucosal dissection.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
MASLD[tiab] OR MASH[tiab] OR "metabolic dysfunction-associated steatotic"[tiab] OR resmetirom[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.